Dugel, P. U., Singh, R. P., Koh, A., Ogura, Y., Weissgerber, G., Gedif, K., . . . Holz, F. G. (2021). HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology (Rochester, Minn.), 128(1), 89. https://doi.org/10.1016/j.ophtha.2020.06.028
Citace podle Chicago (17th ed.)Dugel, Pravin U., et al. "HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration." Ophthalmology (Rochester, Minn.) 128, no. 1 (2021): 89. https://doi.org/10.1016/j.ophtha.2020.06.028.
Citace podle MLA (9th ed.)Dugel, Pravin U., et al. "HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration." Ophthalmology (Rochester, Minn.), vol. 128, no. 1, 2021, p. 89, https://doi.org/10.1016/j.ophtha.2020.06.028.